Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis

Marc Gourevitch, P. Alcabes, W. C. Wasserman, P. S. Arno

Research output: Contribution to journalArticle

Abstract

SETTING: A methadone treatment program with on-site medical care in the Bronx, New York. OBJECTIVE: To define whether costs associated with directly observed preventive therapy (DOPT) of tuberculosis are justified by cases and costs of tuberculosis prevented among persons at high risk for active disease. DESIGN: Detailed data were collected on drug users in treatment regarding human immunodeficiency virus (HIV) and tuberculosis infection and disease, and costs of screening, chemoprophylaxis, direct observation and treatment of active disease. The cost-effectiveness of providing DOPT to this population was modeled. RESULTS: We assessed the impact of providing DOPT to 151 eligible persons. Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285 284 ($563 per person screened) was associated with DOFF ($10274 per case prevented). Direct observation of chemoprophylaxis proved cost-effective if associated with even a 10% increment in overall isoniazid effectiveness compared with self- administered chemoprophylaxis. DOPT costs per tuberculosis case averted remained below the in-patient costs of a single case of drug-sensitive disease across a range of parameter values. CONCLUSIONS: Providing DOPT is a highly cost-effective intervention for drug users in treatment. Commitment of additional resources required for DOPT should be given priority in this and other populations at high risk for tuberculosis.

Original languageEnglish (US)
Pages (from-to)531-540
Number of pages10
JournalInternational Journal of Tuberculosis and Lung Disease
Volume2
Issue number7
StatePublished - 1998

Fingerprint

Directly Observed Therapy
Chemoprevention
Drug Users
Cost-Benefit Analysis
Tuberculosis
Costs and Cost Analysis
Isoniazid
Virus Diseases
Chronic Disease Hospitals
Observation
Cost of Illness
Hospital Costs
Methadone
Therapeutics
HIV
Pharmaceutical Preparations
Population

Keywords

  • Cost-effectiveness
  • Drug users
  • HIV infection
  • Prevention
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. / Gourevitch, Marc; Alcabes, P.; Wasserman, W. C.; Arno, P. S.

In: International Journal of Tuberculosis and Lung Disease, Vol. 2, No. 7, 1998, p. 531-540.

Research output: Contribution to journalArticle

@article{4d0acde0e2d8416883334016a6f30c5a,
title = "Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis",
abstract = "SETTING: A methadone treatment program with on-site medical care in the Bronx, New York. OBJECTIVE: To define whether costs associated with directly observed preventive therapy (DOPT) of tuberculosis are justified by cases and costs of tuberculosis prevented among persons at high risk for active disease. DESIGN: Detailed data were collected on drug users in treatment regarding human immunodeficiency virus (HIV) and tuberculosis infection and disease, and costs of screening, chemoprophylaxis, direct observation and treatment of active disease. The cost-effectiveness of providing DOPT to this population was modeled. RESULTS: We assessed the impact of providing DOPT to 151 eligible persons. Assuming 65{\%} isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285 284 ($563 per person screened) was associated with DOFF ($10274 per case prevented). Direct observation of chemoprophylaxis proved cost-effective if associated with even a 10{\%} increment in overall isoniazid effectiveness compared with self- administered chemoprophylaxis. DOPT costs per tuberculosis case averted remained below the in-patient costs of a single case of drug-sensitive disease across a range of parameter values. CONCLUSIONS: Providing DOPT is a highly cost-effective intervention for drug users in treatment. Commitment of additional resources required for DOPT should be given priority in this and other populations at high risk for tuberculosis.",
keywords = "Cost-effectiveness, Drug users, HIV infection, Prevention, Tuberculosis",
author = "Marc Gourevitch and P. Alcabes and Wasserman, {W. C.} and Arno, {P. S.}",
year = "1998",
language = "English (US)",
volume = "2",
pages = "531--540",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "7",

}

TY - JOUR

T1 - Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis

AU - Gourevitch, Marc

AU - Alcabes, P.

AU - Wasserman, W. C.

AU - Arno, P. S.

PY - 1998

Y1 - 1998

N2 - SETTING: A methadone treatment program with on-site medical care in the Bronx, New York. OBJECTIVE: To define whether costs associated with directly observed preventive therapy (DOPT) of tuberculosis are justified by cases and costs of tuberculosis prevented among persons at high risk for active disease. DESIGN: Detailed data were collected on drug users in treatment regarding human immunodeficiency virus (HIV) and tuberculosis infection and disease, and costs of screening, chemoprophylaxis, direct observation and treatment of active disease. The cost-effectiveness of providing DOPT to this population was modeled. RESULTS: We assessed the impact of providing DOPT to 151 eligible persons. Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285 284 ($563 per person screened) was associated with DOFF ($10274 per case prevented). Direct observation of chemoprophylaxis proved cost-effective if associated with even a 10% increment in overall isoniazid effectiveness compared with self- administered chemoprophylaxis. DOPT costs per tuberculosis case averted remained below the in-patient costs of a single case of drug-sensitive disease across a range of parameter values. CONCLUSIONS: Providing DOPT is a highly cost-effective intervention for drug users in treatment. Commitment of additional resources required for DOPT should be given priority in this and other populations at high risk for tuberculosis.

AB - SETTING: A methadone treatment program with on-site medical care in the Bronx, New York. OBJECTIVE: To define whether costs associated with directly observed preventive therapy (DOPT) of tuberculosis are justified by cases and costs of tuberculosis prevented among persons at high risk for active disease. DESIGN: Detailed data were collected on drug users in treatment regarding human immunodeficiency virus (HIV) and tuberculosis infection and disease, and costs of screening, chemoprophylaxis, direct observation and treatment of active disease. The cost-effectiveness of providing DOPT to this population was modeled. RESULTS: We assessed the impact of providing DOPT to 151 eligible persons. Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285 284 ($563 per person screened) was associated with DOFF ($10274 per case prevented). Direct observation of chemoprophylaxis proved cost-effective if associated with even a 10% increment in overall isoniazid effectiveness compared with self- administered chemoprophylaxis. DOPT costs per tuberculosis case averted remained below the in-patient costs of a single case of drug-sensitive disease across a range of parameter values. CONCLUSIONS: Providing DOPT is a highly cost-effective intervention for drug users in treatment. Commitment of additional resources required for DOPT should be given priority in this and other populations at high risk for tuberculosis.

KW - Cost-effectiveness

KW - Drug users

KW - HIV infection

KW - Prevention

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0031851551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031851551&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 531

EP - 540

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 7

ER -